Financial Performance - The company's operating revenue for 2021 was ¥521,695,665.95, representing a 9.40% increase compared to ¥476,848,910.66 in 2020[19]. - The net profit attributable to shareholders for 2021 was ¥120,201,415.72, a decrease of 14.78% from ¥141,052,780.56 in 2020[19]. - The net profit after deducting non-recurring gains and losses was ¥115,415,204.48, down 14.83% from ¥135,512,748.24 in 2020[19]. - The net cash flow from operating activities increased by 19.71% to ¥199,729,417.14 in 2021, compared to ¥166,849,476.85 in 2020[19]. - The total assets at the end of 2021 were ¥970,306,076.54, a 23.10% increase from ¥788,252,254.49 at the end of 2020[19]. - The net assets attributable to shareholders increased by 19.31% to ¥742,839,394.81 at the end of 2021, compared to ¥622,637,979.09 at the end of 2020[19]. - The basic earnings per share for 2021 was ¥1.75, down 14.63% from ¥2.05 in 2020[19]. - In 2021, the company achieved a revenue of CNY 521.70 million, representing a growth of 9.40% year-over-year, while net profit decreased by 14.78% to CNY 120.20 million[48]. - The average exchange rate of USD to CNY decreased from 6.9346 to 6.4556, resulting in a currency depreciation impact that reduced revenue by CNY 26.40 million[48]. - The cost of goods sold increased by 23.88% year-on-year, primarily due to rising prices of key raw materials, including a 61.22% increase in domestic thionyl chloride and a 51.90% increase in adipic acid[49]. - The gross margin for the pharmaceutical main business decreased to 40.43%, down 6.95% from the previous year, due to increased costs[54]. - Domestic revenue grew significantly by 40.20%, reaching ¥165,980,682.28, while international revenue slightly decreased by 0.77% to ¥355,714,983.67[52]. Research and Development - The company has obtained 31 invention patents and has a complete and professional R&D platform, ensuring continuous optimization of its product pipeline[37]. - The company’s products include three major series: alpha-lipoic acid, phosphatidylcholine, and carnosine, with applications in pharmaceuticals and health products[38]. - The company plans to increase R&D investment in 2022, focusing on the development of key pharmaceutical intermediates and specialty APIs[82]. - The company aims to enhance its R&D team by attracting high-end talent and optimizing the organizational structure to support rapid growth[82]. - The company’s R&D expenses increased by 24.65% year-on-year, reaching ¥28,514,243.16, which represents 5.47% of total revenue[65]. - Research and development expenses rose by 24.65% to ¥28,514,243.16, with a focus on high-end pharmaceutical raw materials and the successful approval of the key project, Arixib, in August 2021[49]. Market and Industry Outlook - The global market for raw materials and intermediates is expected to maintain stable growth, driven by the expiration of patents for original drugs, with an estimated sales value of approximately $198 billion from 2019 to 2024[30]. - The global active pharmaceutical ingredients (API) market was approximately $174.96 billion in 2020 and is projected to reach $245.88 billion by 2026, with a CAGR of 5.84% from 2021 to 2026[31]. - In 2019, China's pharmaceutical raw material manufacturing enterprises achieved main business revenue of 380.37 billion yuan, accounting for 14.6% of the total revenue of large-scale pharmaceutical enterprises in China, with a year-on-year growth of 5.0%[31]. - The Chinese government has issued policies to support the high-quality development of the API industry, emphasizing the development of specialty APIs and innovative APIs[32]. Corporate Governance - The company has a governance structure compliant with laws and regulations, including an independent board of directors and supervisory board[92]. - The company has established independent bank accounts, ensuring no shared accounts with controlling shareholders[92]. - The company has a clear internal management and control system tailored to its operational needs[92]. - The company has appointed independent directors to enhance governance and oversight[94]. - The company held its annual shareholder meeting with 100% investor participation, approving key reports including the 2020 financial report and the 2021 budget[93]. - The company has a total of 5,536,200 shares represented by related shareholders that were excluded from the voting rights during the shareholder meeting[93]. Environmental Responsibility - The company is classified as a key pollutant discharge unit by environmental protection authorities[127]. - The company established a comprehensive environmental protection system combining clean production and end-of-pipe treatment to ensure compliance with pollutant discharge standards[129]. - The company’s wastewater treatment facilities utilize advanced processes such as MVR evaporation and reverse osmosis to meet discharge standards[130]. - The company has received environmental impact assessment approvals for multiple projects, including a 1000 tons/year production of 6,8-dichloro-octanoic acid ethyl ester and related products, approved in November 2010[131]. - The company has maintained compliance with environmental regulations, with no administrative penalties reported during the reporting period[133]. Employee Management - The total number of employees at the end of the reporting period was 466, with 322 in production, 79 in technology, and 6 in sales[113]. - The employee compensation policy combines base salary and performance-based pay, ensuring competitive remuneration[114]. - The company emphasizes talent development through competitive compensation and internal training mechanisms[115]. - The company has established a comprehensive employee social insurance management system, ensuring labor rights and promoting harmonious labor relations[134]. Dividend Distribution - The company plans to distribute a cash dividend of 4.00 CNY per 10 shares to all shareholders, based on a total of 91,670,000 shares[4]. - The company distributed a cash dividend of 4.00 RMB per 10 shares, totaling 36,668,000.00 RMB, which represents 100% of the total profit distribution[116][118]. - The company has no plans for stock dividends or capital reserve transfers during the reporting period[118].
富士莱(301258) - 2021 Q4 - 年度财报